Primary Care/Disease Focus downsizing

[Anonymous]

10 years with Merck, my thoughts on the upcoming 6~9 months. Singular generic. Maxalt generic. Vytorin sales fading. Obviously there has to be cuts. However Lillly BI has 3000 reps selling Tradjenta. Merck needs significant voice for J/J.

I think every region will be looked at based on its business needs at each district level. possibly 1 port 1, 1 port 2, and a flex bag rep (if needed) for each geography. Kinda like a sales force A,B,C??? I do believe cuts will be based on everyone's 2010 and 2011 final evaluations with bucket placements. So, anyone in the bottom 10~15% in EITHER of the previous year is probably vulnerable. You have to think an October timeline with announcements and the new sales structure in place for 2012, January. Now, I am not sure what to think with disease focus. I would say that it will be integrated into the PC territories (just my thoughts). Cmon, its not like the TRA is about to be approved and we need a high science team of specialty reps. Its Zetia. Its Januvia. Selling is the same whether its a specialist or primary care. Right??

Again, this is just a veterans thoughts. I am probably wrong. But if I were a bettin man, this would be the plan for Merck.

 

[Anonymous]

10 years with Merck, my thoughts on the upcoming 6~9 months. Singular generic. Maxalt generic. Vytorin sales fading. Obviously there has to be cuts. However Lillly BI has 3000 reps selling Tradjenta. Merck needs significant voice for J/J.

I think every region will be looked at based on its business needs at each district level. possibly 1 port 1, 1 port 2, and a flex bag rep (if needed) for each geography. Kinda like a sales force A,B,C??? I do believe cuts will be based on everyone's 2010 and 2011 final evaluations with bucket placements. So, anyone in the bottom 10~15% in EITHER of the previous year is probably vulnerable. You have to think an October timeline with announcements and the new sales structure in place for 2012, January. Now, I am not sure what to think with disease focus. I would say that it will be integrated into the PC territories (just my thoughts). Cmon, its not like the TRA is about to be approved and we need a high science team of specialty reps. Its Zetia. Its Januvia. Selling is the same whether its a specialist or primary care. Right??

Again, this is just a veterans thoughts. I am probably wrong. But if I were a bettin man, this would be the plan for Merck.

Are you thinking, three reps per territory.. 1, P1; 1 P2; 1 Flex with remaining support from EBPU? S3s prime candidates?

 

[Anonymous]

Does anyone know if the hospital team will be absorbed into the primary care team?

 

[Anonymous]

Does anyone know if the hospital team will be absorbed into the primary care team?

Most will get absorbed by the Unemployment line.

 

[Anonymous]

10 years with Merck, my thoughts on the upcoming 6~9 months. Singular generic. Maxalt generic. Vytorin sales fading. Obviously there has to be cuts. However Lillly BI has 3000 reps selling Tradjenta. Merck needs significant voice for J/J.

I think every region will be looked at based on its business needs at each district level. possibly 1 port 1, 1 port 2, and a flex bag rep (if needed) for each geography. Kinda like a sales force A,B,C??? I do believe cuts will be based on everyone's 2010 and 2011 final evaluations with bucket placements. So, anyone in the bottom 10~15% in EITHER of the previous year is probably vulnerable. You have to think an October timeline with announcements and the new sales structure in place for 2012, January. Now, I am not sure what to think with disease focus. I would say that it will be integrated into the PC territories (just my thoughts). Cmon, its not like the TRA is about to be approved and we need a high science team of specialty reps. Its Zetia. Its Januvia. Selling is the same whether its a specialist or primary care. Right??

Again, this is just a veterans thoughts. I am probably wrong. But if I were a bettin man, this would be the plan for Merck.

There you go again. Rationalizing your existence. Layoffs have nothing to do with some sorta "share of voice" model. Layoffs are based on cost containment (overhead-i.e. hi salaries) while minimizing legal blowback (demographics) which is why you have a lawyer for a ceo. What "bucket" you "fall into" is serendipity. The last thing, if at all, merck will look at is any sort of "business need," and it will be like being hit by a truck: "But they needed me!" Kinda unsettling huh?

 

[Anonymous]

There you go again. Rationalizing your existence. Layoffs have nothing to do with some sorta "share of voice" model. Layoffs are based on cost containment (overhead-i.e. hi salaries) while minimizing legal blowback (demographics) which is why you have a lawyer for a ceo. What "bucket" you "fall into" is serendipity. The last thing, if at all, merck will look at is any sort of "business need," and it will be like being hit by a truck: "But they needed me!" Kinda unsettling huh?

Extremely. Add to that Frazier who knows business like Obama and it becomes mindblowing.